AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00938223 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 4-peptide and 12-peptide melanoma vaccines
Description: Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN).
Study NCT01314157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isostretching
Description: 12 interventions (two times per week) for 45 minutes
Study NCT02370771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological sampling
Description: Biological sampling to identify by label-free proteomic analysis of a combination of serum biomarkers in patients with Erosive and non erosive hand Osteoarthritis
Study NCT02370771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiographic evaluation
Description: Radiographic assessments using Bone Mineral Analyser and Hand MRI will be done in patients with Erosive and non erosive hand Osteoarthritis
Study NCT02163122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Allergen Challenge
Description: Cat allergen (FelD1) applied directly to the nasal tissues
Study NCT02163122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Exposure Chamber
Description: The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
Study NCT02163122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat allergen (FelD1)
Study NCT02730208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor/Ivacaftor
Description: TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
Study NCT02730208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: IVA 150 mg tablet.
Study NCT02084082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin ER FDC
Description: 1x Linagliptin/Metformin FDC tablet
Study NCT02084082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1x Linagliptin tablet
Study NCT02730208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to TEZ/IVA fixed-dose combination tablet.
Study NCT02730208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to IVA tablet.
Study NCT02084082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 2x Metformin ER tablets
Study NCT02862782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (Ovitrelle 250 mcg mcg - Merck Serono)
Study NCT02862782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh)
Study NCT03569813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP@Home System
Description: The PrEP@Home system includes a home care kit mailed quarterly to participants. The kit has components for self-collection of urine, rectal and pharyngeal swabs, microtube blood collection, and materials for return shipping. Biological tests routinely performed at PrEP follow-up (FU) visits will be done on the specimens. At months 6 and 12, the kit will include materials to assess for protective levels of emtricitabine triphosphate (FTC-TP).~The system includes a study app through which participants may track the mailing of home testing kits, access quarterly surveys, and communicate with study clinicians. The surveys will include domains that physicians assess at PrEP care quarterly FU visits (sexual risk, illicit substance use, PrEP adherence, side effects).~Study Clinicians will review Lab and survey results and if the results show no contraindications for PrEP continuation, the clinician may renew a participant's PrEP prescription. Telemedicine visits will be scheduled as needed.
Study NCT03569813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Control participants will receive clinic-based PrEP follow-up. After the baseline assessment, control participants will receive active linkage to standard, clinic-based PrEP care for their next PrEP care follow-up visit. Participants will also download the control version of the study app, which will contain only research elements pertinent to their participation in the control arm of the study including quarterly surveys. At months 6 and 12, control arm participants will be sent materials for DBS self-collection and return shipping to allow for measurement of the study outcome, emtricitabine triphosphate (FTC-TP).
Study NCT01592747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride (HCl)
Description: Extended Release Dose ranging from 3-15mg/day; administered orally
Study NCT01889758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Generic Hi: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
Study NCT01889758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Generic Lo: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
Study NCT04780451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation in recreational runners
Description: Male recreational runners participated in 12 weeks of endurance training combined with omega-3 fatty acids supplementation. Before starting and at the end of the 12-week cycle, the runners performed an increasing intensity treadmill test where oxygen uptake and VO2 peak were assessed.
Study NCT04780451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 supplementation in recreational runners
Description: Male recreational runners participated in 12 weeks of endurance training combined with omega-3 fatty acids supplementation. Before starting and at the end of the 12-week cycle, the runners performed an increasing intensity treadmill test where oxygen uptake and VO2 peak were assessed.
Study NCT02464904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). The procedure will involve 2 to 3 applications of cryospray on the location of the disease. After establishing cryofrost over a minimum of a 2 x 2 cm area, cryospray will continue for 15 to 20 seconds, allow a thaw period of 60 seconds followed by one to two repeats in the same location before proceeding onto the next location. We will treat a minimum of 6 x 6 cm area in aggregate. The freezing procedure will be video-recorded and freezing locations and time will be recorded. Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection.
Study NCT02464904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection
Study NCT01556906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomitapide
Description: Oral administration with escalating doses administered once daily
Study NCT00651651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Study NCT00651651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Study NCT00651651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Study NCT02032927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine/paracetamol
Description: Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking.
Study NCT02032927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/naloxone
Description: Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking.
Study NCT00842309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-cycloserine
Description: 100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
Study NCT00842309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
Study NCT02448563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity education
Description: Eight weekly in-person groups
Study NCT03965065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sutureless aortic bioprosthesis
Description: Patients will receive a sutureless aortic bioprosthesis
Study NCT03965065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional stented sutured aortic prosthesis
Description: Patients will receive a stented sutured aortic prosthesis
Study NCT03454737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out.~The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration
Study NCT03454737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pure platelet-rich plasma
Description: Under aseptic conditions, in surgical medium, 6 ml of P-PRP will be obtained from 36 ml of autologous peripheral venous blood sample.~The plasma coagulation will be activated by the addition of Cl2Ca at a concentration of 5%.
Study NCT03373630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midline catheter
Description: The catheter will be inserted according to usual practices, after the enrollment of the patient in the study. The follow-up will last until the removal of the catheter, which will also be done according to usual practices. Following the removal, bacteriologic analyses will be performed in order to diagnose any prospective infection.
Study NCT03312894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets
Study NCT03312894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching tablets
Study NCT03312894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching tablets
Study NCT01426334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO
Study NCT01426334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study NCT01426334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01426334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO
Study NCT02070523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VDCLD regimen
Study NCT02070523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDCLD regimen
Study NCT01213407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trivax, Temozolomide, Surgery, Radiotherapy
Description: Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32~Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.~Break: weeks 7, 8, 9, 10.~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31.
Study NCT01213407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide, Surgery, Radiotherapy
Description: Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6~Break: weeks 7, 8, 9, 10~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31
Study NCT03601845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimuli
Description: Visual stimulation while using additional sequencing
Study NCT03601845 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No stimuli
Description: Additional sequencing only
Study NCT03297151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: CONTROL
Description: Food grade mixture of non-essential amino acids in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10955
Study NCT03297151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Concentrate
Description: Whey protein concentrate in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Trade name of product is Carbelac80 Instant Product Reference Number 10431
Study NCT03297151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Hydrolysate
Description: Whey protein concentrate hydrolysate (degree of hydrolysate 27%) in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10468
Study NCT03506087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance care planning coaching session.
Description: A 60-minute in-person coaching session. The advance care planning coach, trained in motivational interviewing, will use a flexible script and checklist to assess the participant's readiness to engage in advance care planning and guide the participant forward in the process, proceeding at the participant's pace. Some participants may complete advance directives while others will not get that far. Some participants may receive a follow-up session 2-4 weeks later. Typically this 20 to 30-minute conversation will be by phone, but it may be conducted at the clinic as indicated for the participant.
Study NCT03506087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed advance care planning materials
Description: Participants are provided with a folder containing an advance care planning guide developed by the Coalition for the Supportive Care of Kidney Patients for persons with Chronic Kidney Disease. The patient folder also contains the advance directive form used by the clinic that is appropriate to the state.
Study NCT03506087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed advance care planning materials
Description: Participants are provided with a folder containing an advance care planning guide developed by the Coalition for the Supportive Care of Kidney Patients for persons with Chronic Kidney Disease. The patient folder also contains the advance directive form used by the clinic that is appropriate to the state.
Study NCT01767909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (Humulin® R U-100)
Description: 20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
Study NCT01767909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
Study NCT02639182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16C3F
Description: Intravenous (IV) infusion
Study NCT02639182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib
Description: Oral
Study NCT01853176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Injection Bupivacaine (Exparel)
Study NCT01853176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard bupivicaine
Study NCT01449409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time asthma care outreach
Description: Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
Study NCT02957578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solo TTD
Description: Placement of tympanostomy tube with Solo TTD
Study NCT02095522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 1mg per day for one month
Study NCT04458883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging
Description: Cardiac Magnetic Resonance Imaging - Cardiac Scan
Study NCT02890290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Marine Protein hydrolysate
Description: The participants will take the supplement in form of tablets and will be instructed to take five tablets twice a day, preferably in relation to meals, however, not the dinner meal. Each tablet contains 300 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Flexipharma AS.
Study NCT02890290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be made based on gum arabicum. The tablets are produced by Flexipharma AS.
Study NCT00002664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: edrecolomab
Study NCT00002664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT04448873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: After at least 2 years of remission of KHE, we compare guided discontinuation with maintenance treatment in pediatric patients with KHE.
Study NCT04448873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: After at least 2 years of remission of KHE, we compare guided discontinuation with maintenance treatment in pediatric patients with KHE.
Study NCT02809521 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Activity Liking
Study NCT04165811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Description: A program consisting of aerobic dance based exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
Study NCT04165811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselling
Description: Only physical activity counseling will be given to the subjects in this group.
Study NCT03902106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: subjects ingest salbutamol
Study NCT03902106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: subjects undergo 6 weeks of endurance training (3 times weekly)